PREVECEUTICAL provides lead pain management peptides update Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update to its non-addictive analgesic program ("Analgesic Program").
Further to the news release of September 2, 2020, the Analgesic Program consisted of an iterative approach to peptide design resulting in a number of second-generation peptide analogues optimized from the most promising first-generation series. Cell and stability testing results correlate well with the pilot animal studies. The peptides demonstrated analgesic activity in a rodent inflammatory pain model at relatively low doses, with the effects lasting for up to two hours. The results further show that the peptides did not affect inflammation in the pain model, suggesting their effects were associated with an opioid-like analgesic effect.
The Company is very pleased with these results and is currently conducting Pharmacokinetic (PK) studies on select lead peptides. The results of this work will be provided shortly.
PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "We are looking forward to the results of the PK studies. This brings us closer to finding non-addictive pain therapies. We will be investigating patenting the lead peptides once the study is completed. The Company is looking forward to adding this to our pipeline of intellectual property".
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com